A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

To learn if giving mosunetuzumab in combination with polatuzumab vedotin, tafasitamab, and lenalidomide can help to control relapsed/refractory FL and DLBCL.

Trial Details

NCT ID
NCT05615636
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Mosunetuzumab
  • Polatuzumab vedotin
  • Tafasitamab
  • Lenalidomide
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Patients in safety run in must meet the following criteria for study entry:
  • A diagnosis of relapsed CD20+ Follicular Lymphoma grade 1-3a
  • A diagnosis of relapsed CD20+ diffuse large B-cell lymphoma
  • Patients in dose expansion must meet the following criteria for study entry:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →